Advertisement

Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization

  • Ladonya Jackson
  • Guangkuo Dong
  • Waleed Althomali
  • Mohammed A. Sayed
  • Wael Eldahshan
  • Babak Baban
  • Maribeth H. Johnson
  • Jessica Filosa
  • Susan C. Fagan
  • Adviye ErgulEmail author
Original Article
  • 11 Downloads

Abstract

A disabling consequence of stroke is cognitive impairment, occurring in 12%–48% of patients, for which there is no therapy. A critical barrier is the lack of understanding of how post-stroke cognitive impairment (PSCI) develops. While 70% of stroke victims present with comorbid diseases such as diabetes and hypertension, the limited use of comorbid disease models in preclinical research further contributes to this lack of progress. To this end, we used a translational model of diabetes to study the development of PSCI. In addition, we evaluated the application of compound 21 (C21), an angiotensin II Type 2 receptor agonist, for the treatment of PSCI by blinding the treatment assignment, setting strict inclusion criteria, and implementing a delayed administration time point. Diabetes was induced by a high-fat diet (HFD) and low-dose streptozotocin (STZ) combination. Control and diabetic rats were subjected to 1 h middle cerebral artery occlusion (MCAO) or sham surgery. Adhesive removal task (ART) and two-trial Y-maze were utilized to test sensorimotor and cognitive function. Three days post-stroke, rats that met the inclusion criteria were administered C21 or vehicle in drinking water at a dose of 0.12 mg/kg/day for 8 weeks. Samples from freshly harvested brains were analyzed by flow cytometry and immunohistochemistry (IHC). Diabetes exacerbated the development of PSCI and increased inflammation and demyelination. Delayed administration of C21 3 days post-stroke reduced mortality and improved sensorimotor and cognitive deficits. It also reduced inflammation and demyelination through modulation of the M1:M2 ratio in the diabetic animals.

Keywords

Stroke Diabetes Inflammation Microglia Angiotensin II Type 2 Receptor (AT2R) 

Notes

Acknowledgments

This study is from the doctoral thesis of Ladonya Jackson, presented to the University of Georgia. The authors would like to thank Dr. Darrell Brann for providing the BV2 cell line and Vicore Pharma for providing C21. We would also like to thank the Electron Microscope and Histology Core at Augusta University for the histological staining of our samples, with a special thanks to Ms. Penny Roon.

Funding

This study was supported by National Institute of Health (NIH) R01 NS104573 to Adviye Ergul and Susan C. Fagan; R01 NS083559, Veterans Affairs (VA) Merit Review (BX000347), VA Senior Research Career Scientist Award (IK BX004471) to Adviye Ergul; and TL1 TR002382 and UL1TR002378 to Ladonya Jackson.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Statement on the Welfare of Animals

All rats were housed in the animal care facility at Augusta University, which is approved by the American Association for Accreditation of Laboratory Animal Care. All experiments were conducted in accordance with the National Institute of Health (NIH) guidelines for the care and use of animals in research. Furthermore, all protocols were approved by the institutional animal care and use committee.

Supplementary material

12975_2019_752_MOESM1_ESM.pptx (712 kb)
ESM 1 Fig. S1 The degree of weight loss correlated with lesion size. In order to set inclusion criteria, we first evaluated the correlation between weight loss at day 3 and the infarct size at day 3. We discovered that weight loss correlated with the size of the infarct (R2 = 0.8), Pearson’s Correlation. Since a 10% drop in weight loss only correlated with a 20% infarct size, we required the drop in weight loss of the included animals to be greater than 10%. Fig. S2 In an effort to ensure inclusion of animals with a significant degree of ischemic injury, a strict inclusion criteria was employed. 3 days after the animals underwent MCAO surgery, those that met the weight loss and sensorimotor deficit criteria were included in the study. Sham diabetic animals trended to show increased inflammation. A) 30 um sections from the B slice were co-stained with IBA-1 and GFAP and 10x images were taken from the structures within the prefrontal cortex, limbic system and OVLT. Images derived from control sham (A) and a diabetic sham groups (B) were Z stacked and quantified throughout the layer. Diabetic sham animals trended to exhibit a chronic upregulation of C) IBA-1+ cells (p < 0.07). Student’s t test, (Control sham C vs Diabetic sham D) + compared to control sham (p < 0.05). No difference was found in D) GFAP+ cells compared to their control counterparts. (n = 5/group). Fig. S3 Delayed C21 administration did not impact blood glucose. Blood glucose ranged from 300–350 mg/dL throughout the majority of the study. Fig. S4 Delayed C21 administration did not impact weight loss post-stroke. There was no significant difference in weight with the treatment of C21. Since weight loss is typically maximized by day 3 post-stroke, the delayed administration of C21 was not administered early enough to prevent significant weight loss, and it also did not later contribute to a larger weight gain. Fig. S5 Flow cytometry gating strategy. Strategy showing how cells were gated for flow cytometric analysis to identify infiltrating macrophages. Path A was utilized to differentiate infiltrating cells from resident cells, while path B was utilized to analyze the M1:M2 ratio. (PPTX 711 kb)

References

  1. 1.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.PubMedGoogle Scholar
  2. 2.
    Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B, et al. Trajectory of cognitive decline after incident stroke. JAMA. 2015;314(1):41–51.CrossRefGoogle Scholar
  3. 3.
    Li W, et al. Post-stroke neovascularization and functional outcomes differ in diabetes depending on severity of injury and sex: potential link to hemorrhagic transformation. Exp Neurol. 2018;311:106–14.CrossRefGoogle Scholar
  4. 4.
    Ward R, et al. Post stroke cognitive impairment and hippocampal neurovascular remodeling: the impact of diabetes and sex. Am J Physiol Heart Circ Physiol. 2018.Google Scholar
  5. 5.
    Hardigan T, Ward R, Ergul A. Cerebrovascular complications of diabetes: focus on cognitive dysfunction. Clin Sci (Lond). 2016;130(20):1807–22.CrossRefGoogle Scholar
  6. 6.
    Ergul A, et al. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets. 2012;12(2):148–58.CrossRefGoogle Scholar
  7. 7.
    Wang Q, et al. Prediabetes is associated with post-stroke cognitive impairment in ischaemic stroke patients. Brain Res. 2018;1687:137–43.CrossRefGoogle Scholar
  8. 8.
    Felsky D, Roostaei T, Nho K, Risacher SL, Bradshaw EM, Petyuk V, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun. 2019;10(1):409.CrossRefGoogle Scholar
  9. 9.
    Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915–25.CrossRefGoogle Scholar
  10. 10.
    Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.CrossRefGoogle Scholar
  11. 11.
    Ma S, et al. Diabetes mellitus impairs white matter repair and long-term functional deficits after cerebral ischemia. Stroke. 2018;49(10):2453–63.CrossRefGoogle Scholar
  12. 12.
    Ladonya Jackson WL, Abdul Y, Dong G, Baban B, Ergul A. Diabetic stroke promotes a sexually dimorphic expansion of T cells. NeuroMolecular Med. 2019;In Press(71).Google Scholar
  13. 13.
    Jackson L, et al. Within the brain: the renin angiotensin system. Int J Mol Sci. 2018;19(3).CrossRefGoogle Scholar
  14. 14.
    Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Eldahshan W, et al. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018;15(1):229.CrossRefGoogle Scholar
  15. 15.
    Alhusban A, Fouda AY, Bindu Pillai, Ishrat T, Soliman S, Fagan SC. Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens. 2015;33(1):170–80.CrossRefGoogle Scholar
  16. 16.
    Ahmed HA, et al. Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - a randomized double- blind pre-clinical study. Behav Brain Res. 2018: 346:29–40.CrossRefGoogle Scholar
  17. 17.
    Fouda AY, Pillai B, Dhandapani KM, Ergul A, Fagan SC. Role of interleukin-10 in the neuroprotective effect of the angiotensin type 2 receptor agonist, compound 21, after ischemia/reperfusion injury. Eur J Pharmacol. 2017;799:128–34.CrossRefGoogle Scholar
  18. 18.
    Ahmed HA, et al. Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-a randomized double- blind pre-clinical study. Behav Brain Res. 2019;359:560–9.CrossRefGoogle Scholar
  19. 19.
    Ishrat T, et al. Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: a randomized, blinded preclinical trial in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2018:271678X18764773.Google Scholar
  20. 20.
    Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, et al. The angiotensin type 2 receptor agonist compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology. 2014;81:134–41.CrossRefGoogle Scholar
  21. 21.
    Bennion DM, et al. Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats. PLoS One. 2017;12(7):e0180738.CrossRefGoogle Scholar
  22. 22.
    Min LJ, et al. Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens. 2014;27(8):1036–44.CrossRefGoogle Scholar
  23. 23.
    Shan BS, et al. Attenuation of stroke damage by angiotensin II type 2 receptor stimulation via peroxisome proliferator-activated receptor-gamma activation. Hypertens Res. 2018;41(10):839–48.CrossRefGoogle Scholar
  24. 24.
    Schwengel K, et al. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J Mol Med (Berl). 2016;94(8):957–66.CrossRefGoogle Scholar
  25. 25.
    Li W, et al. Diabetes worsens functional outcomes in young female rats: comparison of stroke models, tissue plasminogen activator effects, and sexes. Transl Stroke Res. 2017.Google Scholar
  26. 26.
    Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982;217(4562):855–7.CrossRefGoogle Scholar
  27. 27.
    Chen J, Li Y, Chopp M. Intracerebral transplantation of bone marrow with BDNF after MCAo in rat. Neuropharmacology. 2000;39(5):711–6.CrossRefGoogle Scholar
  28. 28.
    Holt LM, Olsen ML. Novel applications of magnetic cell sorting to analyze cell-type specific gene and protein expression in the central nervous system. PLoS One. 2016;11(2):e0150290.CrossRefGoogle Scholar
  29. 29.
    Zhang L, Chopp M, Zhang Y, Xiong Y, Li C, Sadry N, et al. Diabetes mellitus impairs cognitive function in middle-aged rats and neurological recovery in middle-aged rats after stroke. Stroke. 2016;47(8):2112–8.CrossRefGoogle Scholar
  30. 30.
    Kumar A, Alvarez-Croda DM, Stoica BA, Faden AI, Loane DJ. Microglial/macrophage polarization dynamics following traumatic brain injury. J Neurotrauma. 2016;33(19):1732–50.CrossRefGoogle Scholar
  31. 31.
    Hao S, et al. Dietary obesity reversibly induces synaptic stripping by microglia and impairs hippocampal plasticity. Brain Behav Immun. 2016;51:230–9.CrossRefGoogle Scholar
  32. 32.
    Ergul A, et al. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016;7(4):248–60.CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  • Ladonya Jackson
    • 1
    • 2
    • 3
  • Guangkuo Dong
    • 3
  • Waleed Althomali
    • 1
    • 2
  • Mohammed A. Sayed
    • 1
    • 2
  • Wael Eldahshan
    • 1
    • 2
    • 3
  • Babak Baban
    • 4
  • Maribeth H. Johnson
    • 5
  • Jessica Filosa
    • 3
  • Susan C. Fagan
    • 1
    • 2
  • Adviye Ergul
    • 6
    • 7
    Email author
  1. 1.Program in Clinical and Experimental TherapeuticsUniversity of Georgia College of PharmacyAugustaUSA
  2. 2.Charlie Norwood Veterans Affairs Medical CenterAugustaUSA
  3. 3.Physiology, Medical College of GeorgiaAugusta UniversityAugustaUSA
  4. 4.Oral BiologyDental College of GeorgiaAugustaUSA
  5. 5.Department of Neuroscience and Regenerative Medicine, Medical College of GeorgiaAugusta UniversityAugustaUSA
  6. 6.Department of Pathology and Laboratory MedicineMedical University of South CarolinaCharlestonUSA
  7. 7.Ralph H. Johnson Veterans Affairs Medical CenterCharlestonUSA

Personalised recommendations